Working… Menu

The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00165711
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : February 19, 2019
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
Patients who fit the inclusion criteria are admitted into the study. They are given 3 IV injection of MBL in the first week and one tablet three times a day for 16 weeks.

Condition or disease Intervention/treatment Phase
Dementia With Vitamin B12 Deficiency Drug: Mecobalamin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: B Vitamins Dementia
Drug Information available for: Mecobalamin

Primary Outcome Measures :
  1. Mattis dementia rating scale

Secondary Outcome Measures :
  1. Category fluency test
  2. Delirium rating scale
  3. CNPI
  4. MMSE
  5. Plasma homocysteine
  6. Plasma isoprostane

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All


  • Patients with Dementia
  • Serum B12 < 200 pmol/l
  • Serum Homocysteine level > 11.0 micro mol/L


Significant communication problems

  • deafness, dysarthria, dysphasia etc.
  • unstable DM or hypertension
  • alcohol abuse
  • co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure
  • folate < 10 g/dl
  • haemoglobin concentration < 10g/d
  • abnormal thyroid function test or VDRL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00165711

Layout table for location information
China, Hong Kong
Chinese University of Hong Kong
Hong Kong, Hong Kong, China
Sponsors and Collaborators
Eisai Co., Ltd.
Layout table for investigator information
Study Director: Romeo Chu Eisai Asia Regional Services Ltd.
Layout table for additonal information
Responsible Party: Eisai Co., Ltd. Identifier: NCT00165711    
Obsolete Identifiers: NCT00164983
Other Study ID Numbers: AS-006 (MBL-HKG-05-01)
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: December 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin B 12 Deficiency
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Vitamin B Deficiency
Deficiency Diseases
Nutrition Disorders